WO2007011595A3 - Neural regeneration peptides and antioxidants protect neurons from degeneration - Google Patents

Neural regeneration peptides and antioxidants protect neurons from degeneration Download PDF

Info

Publication number
WO2007011595A3
WO2007011595A3 PCT/US2006/026994 US2006026994W WO2007011595A3 WO 2007011595 A3 WO2007011595 A3 WO 2007011595A3 US 2006026994 W US2006026994 W US 2006026994W WO 2007011595 A3 WO2007011595 A3 WO 2007011595A3
Authority
WO
WIPO (PCT)
Prior art keywords
neural regeneration
antioxidants
degeneration
neurons
compositions
Prior art date
Application number
PCT/US2006/026994
Other languages
French (fr)
Other versions
WO2007011595A2 (en
Inventor
Frank Sieg
Original Assignee
Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Inc
Frank Sieg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd, Neuren Pharmaceuticals Inc, Frank Sieg filed Critical Neuren Pharmaceuticals Ltd
Publication of WO2007011595A2 publication Critical patent/WO2007011595A2/en
Publication of WO2007011595A3 publication Critical patent/WO2007011595A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/71—Oxidoreductases (EC 1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Aspects of this invention include compositions for treating conditions in which neurons would otherwise degenerate or die as a result of an insult to the nervous system. Other aspects include methods for treating conditions in which neurons would otherwise degenerate or die as a result of an insult to the nervous system. Compositions include a neural regeneration peptide (NRP) and an antioxidant. The methods include administering to a subject in need thereof, a composition comprising a neural regeneration peptide and an antioxidant. Compositions including one or more NRPs and one or more antioxidants can also be used in vitro, to promote growth and differentiation of neural cell cultures. Kits include one or more NRPs, one or more antioxidants, solvents for preparing solutions, a mixing vial and instructions for use.
PCT/US2006/026994 2005-07-15 2006-07-13 Neural regeneration peptides and antioxidants protect neurons from degeneration WO2007011595A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69964205P 2005-07-15 2005-07-15
US60/699,642 2005-07-15
US71491605P 2005-09-07 2005-09-07
US60/714,916 2005-09-07

Publications (2)

Publication Number Publication Date
WO2007011595A2 WO2007011595A2 (en) 2007-01-25
WO2007011595A3 true WO2007011595A3 (en) 2007-12-21

Family

ID=37669339

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/026994 WO2007011595A2 (en) 2005-07-15 2006-07-13 Neural regeneration peptides and antioxidants protect neurons from degeneration

Country Status (1)

Country Link
WO (1) WO2007011595A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980952B2 (en) 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
WO2003079987A2 (en) 2002-03-20 2003-10-02 University Of Maryland Baltimore A non-selective cation channel in neural cells and methods for treating brain swelling
US10583094B2 (en) 2004-09-18 2020-03-10 University Of Maryland Therapeutic methods that target the NCCA-ATP channel
WO2006121926A2 (en) * 2005-05-06 2006-11-16 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods for their use
EP3103451A1 (en) 2007-01-12 2016-12-14 University of Maryland, Baltimore Targetting ncca-atp channel for organ protection following ischemic episode
CA2691199C (en) 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
ES2433568T3 (en) * 2007-10-17 2013-12-11 Curonz Holdings Company Limited Synthetic analogs of neuronal regeneration peptides
EP2719380A3 (en) * 2008-09-16 2014-07-30 University of Maryland, Baltimore SUR1 inhibitors for therapy
RU2431496C2 (en) * 2009-09-15 2011-10-20 Общество С Ограниченной Ответственностью "Герофарм" Injection dosage form for treating acute ischemic stroke and craniocereberal injury, method for preparing and using
CN101780098A (en) * 2010-03-13 2010-07-21 青岛大学 Rosmarinic acid and myricetin medicament formula and application thereof in treatment of Parkinson disease
EP2659897A1 (en) * 2012-05-02 2013-11-06 Philipps-Universität Marburg Stem cell derived composition for the treatment of acute injury and degenerative diseases
AU2013293645B2 (en) * 2012-07-27 2018-04-12 Curonz Holdings Company Limited Method of treating optic nerve damage, ophthalmic ischemia or ophthalmic reperfusion injury
CN103308674B (en) * 2012-12-20 2018-04-06 周继蓉 Peroxiredoxin IV CIC ELISA and its application
US20160031937A1 (en) * 2013-03-08 2016-02-04 Curonz Holdings Company Limited Neural regeneration peptides and uses therefor
RU2016112931A (en) 2013-10-11 2017-11-16 Терикс Фармасьютикалз Лтд. COMPOSITIONS OF NEW PEPTIDES
US20160296590A1 (en) * 2013-12-04 2016-10-13 Curonz Holdings Company Limited Method of treating or preventing epilepsy or seizures using one or more neural regeneration peptides
CN108771668B (en) * 2018-07-24 2019-10-08 四川九章生物科技有限公司 A kind of drug combination composition and its preparation method and application for treating amyotrophic lateral sclerosis
BR102020005627A2 (en) * 2020-03-20 2021-05-18 Nascimbeni E Silva Wellington bioactive supplement
CN113842461B (en) * 2021-11-04 2023-08-11 杭州诺莘科技有限责任公司 GABA for relieving and treating alcoholism and drunk discomfort A Receptor conjugates, compositions and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042561A2 (en) * 2003-10-31 2005-05-12 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods of use
US20050131212A1 (en) * 2001-08-24 2005-06-16 Neuren Pharmaceuticals Ltd. Neural regeneration peptides and methods for their use in treatment of brain damage

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050131212A1 (en) * 2001-08-24 2005-06-16 Neuren Pharmaceuticals Ltd. Neural regeneration peptides and methods for their use in treatment of brain damage
WO2005042561A2 (en) * 2003-10-31 2005-05-12 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods of use

Also Published As

Publication number Publication date
WO2007011595A2 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
WO2007011595A3 (en) Neural regeneration peptides and antioxidants protect neurons from degeneration
WO2005003320A3 (en) Neuronal differentiation of stem cells
WO2003029418A3 (en) Proliferation and differentiation of stem cells using extracellular matrix and other molecules
WO2005077344A3 (en) Hydantoin derivatives as inhibitors of cellular necrosis
ATE448686T1 (en) ACTRIIB FUSION POLYPEPTIDES AND USES THEREOF
WO2006044204A3 (en) Neuronal progenitors from feeder-free human embryonic stem cell culture
WO2008036374A3 (en) Allogeneic stem cell transplants in non-conditioned recipients
EA033130B1 (en) Methods and compositions for improving cognitive function
WO2007075895A3 (en) Heterocyclic derivatives as modulators of ion channels
WO2010056808A3 (en) Compositions and methods for re-programming and re-differentiating cells
WO2008080134A3 (en) 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
IL190632A0 (en) Biphenyl derivatives and pharmaceutical compositions containing the same
WO2011035335A3 (en) Stabilized liquid and lyophilized adamts13 formulations
WO2007146284A3 (en) Thienopyrimidines useful as modulators of ion channels
WO2011097181A3 (en) Compositions and methods for re-programming cells without genetic modification for treatment of neurological disorders
WO2008157791A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
WO2007035722A8 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
MX2021012041A (en) Methods of promoting thymic epithelial cell and thymic epithelial cell progenitor differentiation of pluripotent stem cells.
WO2006130504A3 (en) Methods for identifying ligands for stem cells and cells derived therefrom
WO2010096572A3 (en) Synthetic diblock copolypeptide hydrogels for use in the central nervous system
WO2005047494A3 (en) Haematopoietic stem cells suitable for transplantation, their preparation and pharmaceutical compositions comprising them
CO6670594A2 (en) Method for the regeneration of polyvinyl polypyrrolidone from a tending fraction of a membrane filter after clarification and stabilization of a fermented yeast beverage
WO2019171174A3 (en) Combination compositions and therapies comprising 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, and methods of making and using same
WO2007109648A8 (en) Compositions and methods for modulating store-operated calcium entry
WO2006130493A3 (en) Heterocycles useful as modulators of ion channels

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06786972

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06786972

Country of ref document: EP

Kind code of ref document: A2